Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Updates on Kate Middleton’s Cancer Journey

    September 16, 2024

    Healthcare communities unite at IHH Singapore Sea Regatta

    September 14, 2024

    Researchers Unveil Speech Clues to Dementia

    September 13, 2024
    Facebook Instagram YouTube TikTok
    Facebook Instagram YouTube TikTok
    Medical Channel Asia
    • Health Conditions
      • FEATURED
        • Men’s Health
        • Women’s Health
        • Sports & Fitness
        • Foot Health
        • Sleep
      • CATEGORIES
        • Alternative & Traditional Therapies
        • Cancer
        • Children’s Health
        • Dental Health
        • Diabetes
      •  
        • Ear, Nose & Throat (ENT)
        • Eyes
        • Foot Health
        • Men’s Health
        • Mental Health
      •  
        • Muscles & Joints
        • Nervous System
        • Skin
        • Sports
        • Thyroid Disease
        • Women’s Health
    • Events
    • Ask a Doctor
    • Visit A Doctor
    • HCP Login
    Medical Channel Asia
    Home»Uncategorized»Groundbreaking Made-in-Singapore Cancer Treatment Set to Enter Clinical Trials
    Uncategorized

    Groundbreaking Made-in-Singapore Cancer Treatment Set to Enter Clinical Trials

    Gerald NgBy Gerald NgJanuary 10, 2023
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Singapore – EBC-129, a groundbreaking new antibody-drug conjugate (ADC), is set to become the first antibody-drug conjugate (ADC) developed in Singapore to be approved for clinical trials by the US Food and Drug Administration (FDA). 

    EBC-129 represents an important step forward in cancer treatment and has the potential to greatly improve the lives of patients with a range of cancer types. This exciting new treatment option selectively targets and destroys cancer cells across a range of solid tumours, leaving healthy cells untouched. Unlike chemotherapy, which can damage healthy cells in the process of targeting cancer cells, ADCs deliver a toxic payload exclusively to cancer cells, potentially resulting in fewer side effects for patients. EBC-129 targets a specific biomarker found in a range of cancer types, including common forms such as lung, gastric, and stomach cancer as well as rarer types like bile duct and pancreatic cancer. 

    EBC-129 has the potential to bring much-needed relief to cancer patients who have exhausted standard therapies. Patients may experience fewer side effects compared to traditional treatment options.

    As described by Dr Andre Choo, deputy executive director of the Agency for Science, Technology and Research’s (A*STAR) Bioprocessing Technology Institute (BTI)., EBC-129 acts like a “magic bullet,” specifically targeting and destroying cancer cells while leaving healthy cells unharmed. The effectiveness of the ADC is expected to be determined approximately six months into the clinical trial.

    EBC-129 is the result of a collaboration between several institutions in Singapore, including the Bioprocessing Technology Institute (BTI), the Experimental Drug Development Centre (EDDC), the National Cancer Centre Singapore (NCCS), and the Institute of Molecular and Cell Biology (IMCB). 

    What happens next?

    The ADC is pending approval from the Health Sciences Authority and relevant ethics boards for a clinical trial in Singapore, expected to begin in late February or early March.  

    The first phase of the clinical trial for EBC-129 will assess the safety and tolerability of the treatment in cancer patients with metastatic solid tumours that are not able to be surgically cured. Following this initial phase, the trial will go on to evaluate the effectiveness of EBC-129 in treating different types of tumours.

    What are antibody-drug conjugates?

    Antibody-drug conjugates (ADCs) are a type of targeted cancer therapy. They are composed of a monoclonal antibody, which is a type of protein that specifically targets certain cells or substances in the body, and a cytotoxic drug, which is a substance that can kill cells. The antibody is linked to the drug in such a way that it delivers the drug directly to the cancer cells. The goal of ADCs is to selectively target and kill cancer cells while minimizing harm to normal, healthy cells. ADCs are typically used to treat cancer that has spread to other parts of the body (metastatic cancer) and are an alternative to chemotherapy, which is a more general treatment that can damage normal cells as well as cancer cells. 

    Several ADCs have been approved for use in cancer treatment. As of June 2022, the FDA has approved 12 ADC cancer therapies, five for solid tumours and seven for haematological malignancies

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Gerald Ng

    Gerald Ng is the current chief editor for Medical Channel Asia. Writing has always been his first love and he has more than a decade of journalism experience after falling in love with reading the newspapers daily growing up in Singapore. His works and interviews have appeared in various media publications including Yahoo!, Straits Times and Channel NewsAsia.

    Related Posts

    Uncategorized

    How Can I Boost My Teen’s Confidence in the Social Media Era?

    August 28, 2024
    Uncategorized

    ALS Patient Regains Speech Through Cutting-Edge Brain Implant

    August 20, 2024
    Uncategorized

    Manila’s Commitment to Elderly Care: Enhancing Health Programmes for Senior Citizens

    August 14, 2024
    Uncategorized

    The Philippines’ HIV Epidemic Moving In The Wrong Direction

    July 31, 2024
    Uncategorized

    Handwashing Crucial in Preventing Hand, Foot, and Mouth Disease (HFMD)

    July 30, 2024
    Uncategorized

    Indonesian Celebrity Cherly Juno Undergoes Tummy Tuck Surgery

    July 19, 2024

    Subscribe to News

    Get the latest sports news from NewsSite about world, sports and politics.

    Editor's Picks

    Updates on Kate Middleton’s Cancer Journey

    September 16, 2024

    Healthcare communities unite at IHH Singapore Sea Regatta

    September 14, 2024

    Researchers Unveil Speech Clues to Dementia

    September 13, 2024

    The Lifeline of Trauma Care and Its Message For Road Safety

    September 13, 2024
    Latest Posts
    Advertisement
    Demo
    Facebook X (Twitter) Pinterest Vimeo WhatsApp TikTok Instagram

    News

    • World
    • US Politics
    • EU Politics
    • Business
    • Opinions
    • Connections
    • Science

    Company

    • Information
    • Advertising
    • Classified Ads
    • Contact Info
    • Do Not Sell Data
    • GDPR Policy
    • Media Kits

    Services

    • Subscriptions
    • Customer Support
    • Bulk Packages
    • Newsletters
    • Sponsored News
    • Work With Us

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2025 ThemeSphere. Designed by ThemeSphere.
    • Privacy Policy
    • Terms
    • Accessibility

    Type above and press Enter to search. Press Esc to cancel.